Vinpocetine - instructions for use, dose, side effects, contraindications

Excipients: ascorbic acid 0.5 mg, sodium disulfite (sodium metabisulphite) 10 mg, alcohol gasoline 10 mg, tartaric acid 10 mg, sorbitol (D-sorbitol) 80 mg, sodium tartrate 10 mg, water for injection - up to 1 ml.

Description:Colorless or slightly colored transparent liquid.

Pharmacotherapeutic group:Cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue.Increases the resistance of neurons to hypoxia; facilitating the transport of oxygen and substrates of energy supply to tissues (due to a decrease in the affinity for erythrocytes, increased absorption and metabolism of glucose, switching it to an energetically more advantageous aerobic direction). Selectively blocks Ca²⁺-dependent phosphodiesterase (PDE); increases the level of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) of the brain. Increases the concentration of ATP and the ratio of ATP / AMP in the brain tissues; enhances the metabolism of noradrenaline and serotonin of the brain; stimulates the ascending branch of the noradrenergic system, has an ontioxidant effect. The vasodilating effect is associated with a direct relaxing effect on the smooth muscles of the vessels of the predominantly brain. Vinpocetine does not cause the phenomenon of "stealing", primarily enhances the blood supply of the ischemic region of the brain, while not changing the blood supply of intact areas. Improves microcirculation in the brain by reducing platelet aggregation, reducing blood viscosity, increasing erythrocyte plasticity.Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant effect on the indices of the systemic circulation.

Pharmacokinetics:The therapeutic concentration for parenteral administration in plasma is 10-20 ng / ml, the volume of distribution is 5.3 l / kg. Easily penetrates through gistogematicheskie barriers (including blood-brain and hemato-ophthalmic barriers). Penetrates into breast milk (0.25% within the first hour), through the placental barrier. T1 / 2 - 4.74-5 hours. It is excreted by the kidneys and intestines in the ratio 3: 2.

Indications:

Neurology: as a symptomatic means for various forms of cerebral circulatory insufficiency (ischemic stroke, restorative stage of hemorrhagic stroke, consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, cerebrovascular atherosclerosis, posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of the choroid and retina (including occlusion of the central artery or vein of the retina).

Decreased perceptual hearing acuity, Meniere's disease, idiopathic tinnitus.

Contraindications:Hypersensitivity, acute phase of hemorrhagic stroke, severe form of coronary heart disease, severe heart rhythm disturbances, pregnancy, lactation, age under 18, intolerance to fructose, deficiency of 1,6-diphosphatase.

Dosing and Administration:

Intravenously drip (infusion rate should not exceed 80 cap / min).

The initial daily dose is 20 mg (in 0.5-1 L of a 0.9% solution of sodium chloride or solutions containing dextrose). The average daily dose at a body weight of 70 kg is 50 mg. With good. tolerance for 2-3 days, the dose of the drug is increased to the maximum - 1 mg / kg / day.

The course of treatment is 10-14 days.

After achieving the improvement, they switch to taking the drug inside.

Side effects:

From the cardiovascular system: changes on the ECG (depression of the ST segment, prolongation of the Q-T interval), tachycardia, extrasystole / lability of blood pressure (more often decrease).

From the central nervous system: sleep disturbance (insomnia, increased drowsiness); dizziness, headache, general weakness.

From the digestive system: dry mouth, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia, phlebitis at the injection site, severe allergic reactions, bronchospasm.

Overdose:

Currently, data on the overdose of vinpocetine are limited.

Treatment for overdose: symptomatic therapy.

Interaction:

A solution of vinpocetine for injection is pharmaceutically incompatible with heparin, solutions containing amino acids.

It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary).

Despite the lack of data confirming the possibility of interaction, it is advisable to use caution when using simultaneously with drugs that affect the central nervous system, antiarrhythmics and anticoagulants.

Special instructions:

When introducing solutions of vinpocetine containing sorbitol, in patients with diabetes should monitor blood glucose.

In the case of the initial extension of the Q-T interval, as well as simultaneous use with drugs extending the Q-T interval,During the treatment with vinpocetine, periodic ECG monitoring is necessary.

Effect on the ability to drive transp. cf. and fur:

With intravenous administration Vinpocetine can cause dizziness, in connection with which the first introductions recommend increased caution in driving and working mechanisms.

Form release / dosage:Concentrate for the preparation of solution for infusions 5 mg / ml.

Packaging:2 ml per ampoule of light-protective glass. 5 ampoules per circuit cell box made of polyvinylchloride film and aluminum foil (or without foil). 1 or 2 contour mesh packages with a scarifier ampoule ceramic or knife for opening ampoules and instructions for use are placed in a pack of cardboard. When using ampoules with a fracture ring or break point, the knife or scarifier is not inserted.

Storage conditions:Store in a dark place at a temperature of 10 to 30 ° C. Keep out of the reach of children.

Shelf life:2 years. Do not use expiration date indicated on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-000135

Date of registration:11.01.2011 / 20.11.2015

Expiration Date:11.01.2016

Date of cancellation:2016-12-16

The owner of the registration certificate:BINNOFARM, CJSC BINNOFARM, CJSC Russia

Manufacturer: & nbsp

BINNOFARM, CJSC Russia

STATE FACTORY OF MEDICAL PREPARATIONS, FSUE Russia

Representation: & nbspBINNOFARM CJSC BINNOFARM CJSC Russia

Information update date: & nbsp18.02.2017

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)